This inventor holds 6 USPTO granted patents and 5 published patent applications, plus 3 CIPO patents and 3 EPO patents. Top assignees: University of Basel, Piqur Therapeutics Ag, Applied Research Systems Ars Holding N.v.. Active years: 2007-2026.
Company Filing History:
3 out of 72 
2 out of 4 
1 out of 156 Years Active: 2007-2026
Title: Matthias Wymann: Innovator in Pharmaceutical Chemistry
Introduction
Matthias Wymann is a notable inventor based in Bern, Switzerland. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds for therapeutic applications. With a total of five patents to his name, Wymann's work focuses on innovative solutions for treating disorders mediated by lipid kinases.
Latest Patents
Wymann's latest patents include the invention of difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines. These compounds are classified as phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR), and PI3K-related kinase (PIKKs) inhibitors. The compounds are characterized by a specific formula, wherein certain components are nitrogen or carbon-based, with the requirement that at least two of these components are nitrogen. These innovative compounds are designed to be effective either alone or in combination with other therapeutic agents for treating various disorders.
Career Highlights
Throughout his career, Matthias Wymann has worked with prominent organizations, including Piqur Therapeutics AG and Universität Basel. His experience in these institutions has allowed him to advance his research and contribute to the development of groundbreaking pharmaceutical solutions.
Collaborations
Wymann has collaborated with esteemed colleagues such as Vladimir C